WO2008116135A3 - Topical formulations having enhanced bioavailability - Google Patents

Topical formulations having enhanced bioavailability Download PDF

Info

Publication number
WO2008116135A3
WO2008116135A3 PCT/US2008/057786 US2008057786W WO2008116135A3 WO 2008116135 A3 WO2008116135 A3 WO 2008116135A3 US 2008057786 W US2008057786 W US 2008057786W WO 2008116135 A3 WO2008116135 A3 WO 2008116135A3
Authority
WO
WIPO (PCT)
Prior art keywords
topical formulations
enhanced bioavailability
lipophilic bioactive
benefit
utilized
Prior art date
Application number
PCT/US2008/057786
Other languages
French (fr)
Other versions
WO2008116135A2 (en
Inventor
John Patrick Mccook
Niven Rajin Narain
Indushekhar Persaud
Original Assignee
Pathfinder Man Inc
John Patrick Mccook
Niven Rajin Narain
Indushekhar Persaud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2009010170A priority Critical patent/MX337408B/en
Application filed by Pathfinder Man Inc, John Patrick Mccook, Niven Rajin Narain, Indushekhar Persaud filed Critical Pathfinder Man Inc
Priority to ES08732635T priority patent/ES2755840T3/en
Priority to EP19192556.9A priority patent/EP3607937A1/en
Priority to MX2015000284A priority patent/MX363435B/en
Priority to EP08732635.1A priority patent/EP2136787B1/en
Priority to BRPI0809164A priority patent/BRPI0809164B8/en
Priority to CA2680825A priority patent/CA2680825C/en
Priority to MX2013012936A priority patent/MX352434B/en
Priority to AU2008228764A priority patent/AU2008228764B2/en
Publication of WO2008116135A2 publication Critical patent/WO2008116135A2/en
Publication of WO2008116135A3 publication Critical patent/WO2008116135A3/en
Priority to NO20093032A priority patent/NO20093032L/en
Priority to AU2014202278A priority patent/AU2014202278C1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A61K8/355—Quinones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent.
PCT/US2008/057786 2007-03-22 2008-03-21 Topical formulations having enhanced bioavailability WO2008116135A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BRPI0809164A BRPI0809164B8 (en) 2007-03-22 2008-03-21 COMPOSITION FOR TOPICAL ADMINISTRATION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOSITION
ES08732635T ES2755840T3 (en) 2007-03-22 2008-03-21 Topical formulations that have increased bioavailability
EP19192556.9A EP3607937A1 (en) 2007-03-22 2008-03-21 Topical formulations having enhanced bioavailability
MX2015000284A MX363435B (en) 2007-03-22 2008-03-21 Topical formulations having enhanced bioavailability.
EP08732635.1A EP2136787B1 (en) 2007-03-22 2008-03-21 Topical formulations having enhanced bioavailability
MX2009010170A MX337408B (en) 2007-03-22 2008-03-21 Topical formulations having enhanced bioavailability.
CA2680825A CA2680825C (en) 2007-03-22 2008-03-21 Topical formulations having enhanced bioavailability
MX2013012936A MX352434B (en) 2007-03-22 2008-03-21 Topical formulations having enhanced bioavailability.
AU2008228764A AU2008228764B2 (en) 2007-03-22 2008-03-21 Topical formulations having enhanced bioavailability
NO20093032A NO20093032L (en) 2007-03-22 2009-09-21 Topical formulations with increased bioavailability
AU2014202278A AU2014202278C1 (en) 2007-03-22 2014-04-28 Topical formulations having enhanced bioavailability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91955407P 2007-03-22 2007-03-22
US60/919,554 2007-03-22

Publications (2)

Publication Number Publication Date
WO2008116135A2 WO2008116135A2 (en) 2008-09-25
WO2008116135A3 true WO2008116135A3 (en) 2008-12-24

Family

ID=39766784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/057786 WO2008116135A2 (en) 2007-03-22 2008-03-21 Topical formulations having enhanced bioavailability

Country Status (10)

Country Link
US (4) US8454945B2 (en)
EP (2) EP2136787B1 (en)
AU (2) AU2008228764B2 (en)
BR (1) BRPI0809164B8 (en)
CA (2) CA2823407C (en)
ES (1) ES2755840T3 (en)
MX (3) MX363435B (en)
NO (1) NO20093032L (en)
WO (1) WO2008116135A2 (en)
ZA (1) ZA201400071B (en)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0752317A (en) * 1993-08-13 1995-02-28 Asahi Shiyueebell Kk Laminate
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
JP5376761B2 (en) * 2004-02-23 2013-12-25 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー Topical delivery of nitric oxide to improve body and skin appearance
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
ES2429443T3 (en) * 2004-04-19 2013-11-14 Strategic Science & Technologies, Llc Transdermal supply of beneficial substances by means of an environment of high ionic strength
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
ES2645630T3 (en) 2008-02-04 2017-12-07 Ferring B.V. Monolithic intravaginal rings comprising progesterone and manufacturing methods and uses thereof
WO2009101412A1 (en) * 2008-02-13 2009-08-20 Cipla Limited Topical pharmaceutical composition
WO2009126764A1 (en) * 2008-04-11 2009-10-15 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
GB2465746B (en) * 2008-11-21 2011-02-16 Fortune Apex Dev Ltd Pharmaceutical composition for topical application
WO2010077723A1 (en) * 2009-01-05 2010-07-08 Hauck John F Method for treating nocturia
US9775802B2 (en) 2009-03-24 2017-10-03 Bausch & Lomb Incorporated Method for preparing suspensions of low-solubility materials
US20100247666A1 (en) * 2009-03-24 2010-09-30 Macleod Steven K Method for Preparing Suspensions of Low-Solubility Materials
SG175373A1 (en) 2009-04-28 2011-11-28 Surmodics Inc Devices and methods for delivery of bioactive agents
JP2012526828A (en) * 2009-05-11 2012-11-01 バーグ バイオシステムズ，エルエルシー Methods for treating metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmentally affecting factors
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US8604081B2 (en) 2009-06-24 2013-12-10 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
AU2015203547B2 (en) * 2009-06-24 2017-05-18 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
US20120251525A1 (en) * 2009-06-30 2012-10-04 Streeper Robert T Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules
PL2387391T3 (en) * 2009-07-24 2017-09-29 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Method for developing a liquid composition to be applied to the skin as a foam and a composition that can be applied topically
BR112012012789A2 (en) 2009-11-27 2016-08-16 Nuvo Res Inc topical ibuprofen formulations
US20110150798A1 (en) * 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for increasing cellular far and bleaching skin
US20110150856A1 (en) 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
ES2664793T3 (en) * 2010-03-12 2018-04-23 Berg Llc Intravenous formulations of coenzyme Q10 (CoQ10) and methods of use thereof
CN103200932A (en) * 2010-06-23 2013-07-10 布莱特赛德创新有限公司 Lecithin carrier vesicles and methods of making the same
CN103124556B (en) * 2010-09-30 2015-10-14 积水医疗株式会社 Patch
WO2012092525A1 (en) * 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Cox-2 inhibitors and related compounds, and systems and methods for delivery thereof
JP2014501286A (en) * 2010-12-29 2014-01-20 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー Transdermal delivery of treatment for fungal infections and other indications
CN103442723A (en) * 2010-12-29 2013-12-11 战略科学与技术有限责任公司 Systems and methods for treatment of allergies and other indications
PT2658551T (en) 2010-12-29 2020-07-24 Strategic Science & Tech Llc Treatment of erectile dysfunction and other indications
JP5864615B2 (en) * 2011-01-25 2016-02-17 ザ プロクター アンド ギャンブルカンパニー Liposomes and personal care compositions containing the same
US20160235669A1 (en) * 2011-03-21 2016-08-18 Food Industry Research And Development Institute Process for preparing water dispersions containing high concentration of nano/submicron, hydrophobic, functional compounds and water dispersions obtainable therefrom
ES2762451T3 (en) 2011-04-04 2020-05-25 Berg Llc Treatment of tumors of the central nervous system with coenzyme Q10
US9757497B2 (en) 2011-05-20 2017-09-12 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
US9861727B2 (en) 2011-05-20 2018-01-09 Surmodics, Inc. Delivery of hydrophobic active agent particles
US10213529B2 (en) 2011-05-20 2019-02-26 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
JP5932993B2 (en) 2011-06-17 2016-06-08 バーグ エルエルシー Inhalable pharmaceutical composition
KR101808078B1 (en) * 2011-08-10 2017-12-13 주식회사 아이피어리스 Liposome preparation using lysolecithin and glycerophosphocholine, and personal care composition comprising the same
JP2013060393A (en) * 2011-09-13 2013-04-04 Nitto Denko Corp Composition for enhancing transdermal absorption and patch preparation
JP5820206B2 (en) 2011-09-13 2015-11-24 日東電工株式会社 Transdermal absorption enhancing composition and patch preparation
JP5820207B2 (en) 2011-09-13 2015-11-24 日東電工株式会社 Transdermal absorption enhancing composition and patch preparation
CN102366409B (en) * 2011-09-14 2013-03-20 海南灵康制药有限公司 Nizatidine liposome solid preparation
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (en) 2011-11-23 2021-09-02 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
US9468599B2 (en) * 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
AU2013267166A1 (en) 2012-06-01 2014-12-18 Berg Llc Treatment of solid tumors using Coenzyme Q10
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
CN102727438B (en) * 2012-06-29 2014-07-02 海南美兰史克制药有限公司 Repaglinide liposome solid preparation
EP2877155B1 (en) 2012-07-26 2020-10-28 Camurus AB Opioid formulations
CA2890205C (en) * 2012-11-05 2020-12-22 Surmodics, Inc. Composition and method for delivery of hydrophobic active agents
US11246963B2 (en) 2012-11-05 2022-02-15 Surmodics, Inc. Compositions and methods for delivery of hydrophobic active agents
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
EP2948134B1 (en) 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
US20140243300A1 (en) * 2013-02-28 2014-08-28 Precision Dermatology, Inc. Controlling the Bioavailability of Active Ingredients in Topical Formulations
US20140243299A1 (en) * 2013-02-28 2014-08-28 Precision Dermatology, Inc. Topical Formulations of Corticosteroids with Enhanced Bioavailability
US9511144B2 (en) 2013-03-14 2016-12-06 The Proctor & Gamble Company Cosmetic compositions and methods providing enhanced penetration of skin care actives
US20140276360A1 (en) * 2013-03-15 2014-09-18 Abbott Cardiovascular Systems Inc. Electrophorectic drug coated balloon and conductive polymer coating
EA032775B1 (en) 2013-04-08 2019-07-31 Берг Ллк Methofs of treating cancer using coenzyme q10 combination therapies
JP6595478B2 (en) 2013-09-04 2019-10-23 バーグ エルエルシー Cancer treatment by continuous injection of coenzyme Q10
CN103432073A (en) * 2013-09-11 2013-12-11 中国药科大学 Tumor-targeted nanometer preparation and preparation method thereof
US20150083146A1 (en) * 2013-09-23 2015-03-26 Verso PV, LLC Personal vaporizer liquid for emulsifying oil-soluble compounds and resins
US20150174254A1 (en) * 2013-12-23 2015-06-25 Mcneil-Ppc, Inc. Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
US20150283163A1 (en) * 2014-04-04 2015-10-08 Organic Medical Ventures, L.L.C. Muscle treatment composition and method making same
JP2017516768A (en) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． Natural combination hormone replacement therapy and therapy
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US11007161B1 (en) 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US10251871B2 (en) * 2015-02-05 2019-04-09 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
US20160346219A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US9610242B2 (en) * 2015-08-18 2017-04-04 Concept Labs, Inc. Water-gel emulsion compositions and methods
US20170106020A1 (en) * 2015-10-19 2017-04-20 Stanley James Harless Anesthetic/analgesic composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (en) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 Steroid hormone pharmaceutical composition
AU2017285725B2 (en) * 2016-06-13 2021-08-19 Uti Limited Partnership Methods and compositions for modulating opioid withdrawal symptoms
CN108066767A (en) * 2016-11-17 2018-05-25 北京科百大科技有限责任公司 A kind of self-emulsification solid composition of the drug of class containing ivermectin of stabilization
US10898446B2 (en) 2016-12-20 2021-01-26 Surmodics, Inc. Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces
EP3565520A4 (en) 2017-01-06 2020-08-19 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
WO2018172511A1 (en) * 2017-03-24 2018-09-27 Albarano Teo Pharmaceutical compositions
JP7173992B2 (en) 2017-05-17 2022-11-17 バーグ エルエルシー Use of coenzyme Q10 preparations in the treatment and prevention of epidermolysis bullosa
JP7376105B2 (en) * 2017-09-11 2023-11-08 アトッサ・セラピューティクス・インコーポレイテッド Topical compositions and treatment methods
AU2018329202B2 (en) 2017-09-11 2022-10-27 Atossa Therapeutics, Inc. Methods for making and using endoxifen
EP3681479B1 (en) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
CN107522735A (en) * 2017-09-21 2017-12-29 安徽元创科技有限公司 In the method for solvent method production low viscosity phospholipid prod
JP2021530463A (en) 2018-07-02 2021-11-11 パルヴェラ セラピューティクス、インク． Anhydrous composition of mTOR inhibitor and how to use it
AU2020272127B2 (en) 2019-04-12 2022-12-08 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner and methods of making and using the same
CN114007634A (en) 2019-08-07 2022-02-01 安内拉制药公司 Composition for treating alopecia
US20210322339A1 (en) 2019-11-20 2021-10-21 Berg Llc Combination therapy of coenzyme q10 and radiation for treatment of glioma
CN111166735B (en) * 2020-01-15 2023-08-18 延边大学 Use of bis- (2-ethylheptyl) phthalate for inhibiting fat accumulation
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN111407893A (en) * 2020-04-26 2020-07-14 深圳大学 Application of inhibitor of p38-MAPK signal pathway in preparing medicine for treating nasopharyngeal carcinoma
EP4142692A4 (en) * 2020-04-30 2024-05-22 Blue Sky Innovation, LLC Superoxide dismutase compositions and methods
US11179353B1 (en) * 2020-09-22 2021-11-23 Rythera Therapeutics, Inc. Composition and method for prevention and treatment of radiation dermatitis
WO2022155341A1 (en) * 2021-01-13 2022-07-21 Dyve Biosciences, Inc. Transdermal formulations for phosphodiesterase-5 inhibitors
KR20230000506A (en) * 2021-06-24 2023-01-03 주식회사 종근당 Pharmaceutical combination preparation comprising candesartan, amlodipine and atorvastatin
BE1030538B1 (en) * 2022-05-18 2023-12-19 Bogaert Gina Van Liposomal preparation containing encapsulated hormones, method of production and use
CN114939115B (en) * 2022-06-09 2023-07-25 上海智同医药科技有限公司 Pharmaceutical composition and micropill and capsule prepared from same
CN115069241A (en) * 2022-06-10 2022-09-20 同济大学 Phosphine-assisted patch modulation loaded gold nanocluster, preparation method and catalytic application
WO2024174011A1 (en) * 2023-02-24 2024-08-29 Rossi Bergmann Bartira Liposome, method for preparing a liposome, intranasal composition comprising a liposome, method for preparing an intranasal composition, kit and use of the composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219472A1 (en) * 2002-05-23 2003-11-27 Pauletti Giovanni M. Compositions and method for transmucosal drug delivery and cryoprotection
US20050281772A1 (en) * 2004-06-17 2005-12-22 Bromley Philip J Compositions for mucosal delivery of agents

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525350A (en) 1975-02-20 1985-06-25 The New England Institute, Inc. Methods of stimulating host defense system with coenzymes Q4 to Q.sub.1
IT1157269B (en) 1982-03-19 1987-02-11 Seuref Ag NEW PHARMACEUTICAL FORMULATIONS CONTAINING COENZYME Q10 SUITABLE FOR TOPICAL ADMINISTRATION
JPS58201711A (en) 1982-05-19 1983-11-24 Eisai Co Ltd Coated liposome containing ubidecarenone
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US5651991A (en) 1987-10-28 1997-07-29 Nippon Shinyaku Co. Ltd. Drug carriers
GB8811410D0 (en) * 1988-05-13 1988-06-15 Unilever Plc Treatment of skin disorders
US5015483A (en) 1989-02-09 1991-05-14 Nabisco Brands, Inc. Liposome composition for the stabilization of oxidizable substances
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5962243A (en) 1990-04-18 1999-10-05 Board Of Regents, The University Of Texas System Methods for the identification of farnesyltransferase inhibitors
ES2067255T3 (en) 1990-11-14 1995-03-16 Oreal NON-IONIC AMPHIFYL COMPOUNDS DERIVED FROM GLYCEROL, ITS PREPARATION PROCEDURE, CORRESPONDING INTERMEDIATE COMPOUNDS AND COMPOSITIONS CONTAINING SUCH COMPOUNDS.
SE502569C2 (en) 1991-05-31 1995-11-13 British Tech Group Use of an immunologically inert matrix of a sterol and saponins which can form spherical nanoparticles of narrow size distribution such as drug carriers, particles, composition and kits
US5378461A (en) 1991-07-12 1995-01-03 Neigut; Stanley J. Composition for the topical treatment of skin damage
US6461593B1 (en) 1992-02-19 2002-10-08 Biomedical And Clinical Research Therapy with coenzyme Q10 to reduce subgingival microorganisms in patients with periodontal disease
WO1993016704A1 (en) 1992-02-24 1993-09-02 East Carolina University Method of inhibiting carcinogenesis by treatment with dehydroepiandrosterone and analogs thereof
US5602184A (en) 1993-03-03 1997-02-11 The United States Of America As Represented By Department Of Health And Human Services Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
EP0616801B1 (en) 1993-03-24 1998-05-27 Novartis AG Process for preparing a liposome dispersion at high pressure
US7083572B2 (en) 1993-11-30 2006-08-01 Bristol-Myers Squibb Medical Imaging, Inc. Therapeutic delivery systems
DE4410238A1 (en) 1994-03-25 1995-09-28 Beiersdorf Ag Skin care products
US20020049422A1 (en) 1994-03-31 2002-04-25 Brewitt Barbara A. Homeopathic preparations
JPH10509732A (en) 1994-12-06 1998-09-22 ライアン・ファーマスーティカルス・インコーポレーテッド Water-soluble ubiquinone compositions, prodrugs and related methods
US6005086A (en) 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
DE19537027A1 (en) 1995-10-05 1997-04-10 Beiersdorf Ag Skin care product for old skin
US5944012A (en) 1996-03-25 1999-08-31 Pera; Ivo E. Method for dispensing antioxidant vitamins by inhalation background of the invention
DE19615577A1 (en) 1996-04-19 1997-10-23 Beiersdorf Ag Use of salicin as an anti-irritative agent in cosmetic and topical dermatological preparations
US5891465A (en) 1996-05-14 1999-04-06 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
GB9625895D0 (en) 1996-12-13 1997-01-29 Riley Patrick A Novel compound useful as therapeutic agents and assay reagents
US20040228910A1 (en) 1997-02-11 2004-11-18 Mse Pharmazeutika Gmbh Transdermal, oral and intravenous formulations of 2, 3-dimethoxy-5-methyl-6-decaprenyl-1, 4-benzoquinone
US20020155151A1 (en) 1997-02-11 2002-10-24 Franz Enzmann Transdermal, oral and intravenous preparations of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone
US6228891B1 (en) 1997-02-12 2001-05-08 Mse Pharmazeutika Gmbh Use of 2,3-dimethoxy-5-methyl-6-decaprenyl-1,4-benzoquinone
US6372234B1 (en) 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6599513B2 (en) 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
AU9221698A (en) 1997-09-04 1999-03-22 Biozone Laboratories, Inc. Oral liposomal delivery system
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
AU1289899A (en) 1997-10-31 1999-05-24 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6372880B1 (en) 1997-12-25 2002-04-16 Mitsui Chemicals, Inc. Copolymer and process for preparing the same
CA2736981A1 (en) 1998-04-14 1999-10-21 Kyowa Hakko Bio Co., Ltd. Process for producing isoprenoid compounds by microorganisms
US6503523B2 (en) 1998-05-07 2003-01-07 Gs Development A.B. Skin care agents containing combinations of active agents consisting of vitamin a derivatives and UBI- or plastoquinones
DE19828081C2 (en) 1998-06-24 2000-08-10 Cognis Deutschland Gmbh W / O emulsion bases
WO2000004230A1 (en) 1998-07-16 2000-01-27 Cognis Deutschland Gmbh Use of pit emulsions
US6048886A (en) 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
US20040034107A1 (en) 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
US6803193B1 (en) 1999-06-23 2004-10-12 The Penn State Research Foundation Methods to identify modulators of the mevalonate pathway in sterol synthesis
ES2247749T3 (en) 1999-07-02 2006-03-01 Cognis Ip Management Gmbh MICROCAPSULES III.
US20030104080A1 (en) 1999-09-07 2003-06-05 Singh Parashu Ram Topical urea composition
US6630160B1 (en) 1999-09-07 2003-10-07 Genetic Services Management, Inc. Process to modulate disease risk with doses of a nutraceutical
US20060204458A1 (en) * 2000-10-26 2006-09-14 Holloway William D Jr Anti-aging methods and composition
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7083780B2 (en) 1999-12-11 2006-08-01 Cognis Deutschland Gmbh & Co. Kg Cosmetic composition containing hydroxyethers
WO2001045661A2 (en) 1999-12-20 2001-06-28 Cognis France, S.A. Cosmetic and/or pharmaceutical preparations
FR2804864B1 (en) 2000-02-11 2003-04-04 Serobiologiques Lab Sa EXTRACTS OF RESIDUES FROM THE MANUFACTURE OF WINE AND THEIR USE IN COSMETICS OR PHARMACOLOGY
US20020044913A1 (en) 2000-02-11 2002-04-18 Hamilton Nathan D. Cosmetics to support skin metabolism
DE10007322A1 (en) 2000-02-17 2001-08-23 Cognis Deutschland Gmbh Pearlescent agents
EP1127567B1 (en) 2000-02-17 2010-09-01 Basf Se Aqueous dispersions of water insoluble organic sunscreens
FR2805464B1 (en) 2000-02-25 2003-02-14 Serobiologiques Lab Sa COSMETIC PREPARATIONS CONTAINING EXTRACTS FROM THE PLANT MOURERA FLUVIAUS
DE10009996B4 (en) 2000-03-02 2005-10-13 Cognis Ip Management Gmbh Solid granules with monodisperse particle size distribution, a process for their preparation and their use
WO2001072262A2 (en) 2000-03-27 2001-10-04 Schott Glas New cosmetic, personal care, cleaning agent, and nutritional supplement compositions comprising bioactive glass and methods of making and using the same
US6447760B2 (en) * 2000-05-08 2002-09-10 Playtex Products, Inc. Sunless tanning compositions
US6468552B1 (en) 2000-06-02 2002-10-22 Neutrogena Corporation Stabilized compositions containing oxygen-labile active agents
DE10031703A1 (en) 2000-06-29 2002-01-10 Beiersdorf Ag Use of calcium-releasing or binding substances for targeted scavenging or strengthening of the barrier function of the skin
EP1170015A1 (en) 2000-07-06 2002-01-09 Laboratoires Serobiologiques(Societe Anonyme) Use of extracts of the fungus Grifola frondosa
DE10033022A1 (en) 2000-07-07 2002-01-17 Cognis Deutschland Gmbh aerosols
DE10034619A1 (en) 2000-07-17 2002-01-31 Cognis Deutschland Gmbh Wax-based opacifier formulations, used in detergents, pharmaceutical formulations and especially cosmetics, contain emulsifier mixture of alk(en)yl-oligoglycoside and fatty acid partial glyceride
DE10036655A1 (en) 2000-07-26 2002-02-07 Basf Ag Cosmetic or dermatological preparations to prevent skin damage from peroxides
DE10036799A1 (en) 2000-07-28 2002-02-07 Beiersdorf Ag New treatment for hair and scalp
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
FR2813195B1 (en) 2000-08-29 2003-04-04 Serobiologiques Lab Sa USE OF CASSIA ALATA PLANT EXTRACTS IN CARE PRODUCTS
DE10048260A1 (en) 2000-09-29 2002-04-11 Beiersdorf Ag Cosmetic or dermatological composition for combating undesirable skin pigmentation, contains aminoguanidine or its derivatives
DE10053328A1 (en) 2000-10-27 2002-05-08 Cognis Deutschland Gmbh Cosmetic preparations
US20070003536A1 (en) 2000-11-21 2007-01-04 Zimmerman Amy C Topical skin compositions, their preparation, and their use
DE10064818A1 (en) 2000-12-22 2002-06-27 Basf Ag Use of chroman derivatives in cosmetic or dermatological preparations
US6806069B2 (en) 2001-01-09 2004-10-19 Pharmachem Laboratories, Inc. Ubiquinone composition and methods related thereto
FR2819414A1 (en) 2001-01-15 2002-07-19 Cognis France Sa COSMETIC AND / OR PHARMACEUTICAL PREPARATIONS COMPRISING EXTRACTS FROM PLANTS RESOURCING
NL1017205C2 (en) 2001-01-26 2002-07-29 Adriaan Emanuel Hendricus Wiel Medicinal and cosmetic application of hops and coenzyme Q10.
DE10113050A1 (en) 2001-03-15 2002-09-19 Beiersdorf Ag Self-foaming or foamed cosmetic or dermatological composition comprises a specified emulsifier system, a lipid phase, a gas and an organic hydrocolloid
DE10113046A1 (en) 2001-03-15 2002-09-26 Beiersdorf Ag Self-foaming product for dermatological and cosmetic products comprises an emulsifier system, a lipid phase, gas, organic hydrocolloid and a solid body
DE10113053A1 (en) 2001-03-15 2002-09-19 Beiersdorf Ag Self-foaming or foamed cosmetic or dermatological composition comprises a specified emulsifier system, a lipid phase, a gas, a gelling agent and a hydrocolloid
ATE327006T1 (en) 2001-03-23 2006-06-15 Oreal SKIN TREATMENT PRODUCTS CONTAINING FIBERS AND UBICHINONES
US20030031688A1 (en) 2001-04-02 2003-02-13 Dipak Ghosh Cosmetic composition with improved skin moisturizing properties
US6727234B2 (en) 2001-04-03 2004-04-27 University Of Iowa Research Foundation Isoprenoid analog compounds and methods of making and use thereof
DE10118269A1 (en) 2001-04-12 2002-10-17 Cognis Deutschland Gmbh Production of polyetherurethane thickeners, useful in cosmetic compositions for, e.g. skin or hair, comprises reacting an ethoxylated fatty alcohol with an aliphatic di- or triisocyanate
US6686485B2 (en) 2001-04-19 2004-02-03 Daniel David West Synthesis of coenzyme Q10, ubiquinone
US6582723B2 (en) 2001-05-03 2003-06-24 Wayne F. Gorsek Cancer immune composition for prevention and treatment of individuals
JP3742602B2 (en) 2001-05-09 2006-02-08 株式会社カネカ Stable solution of reduced coenzyme Q
JP4603192B2 (en) 2001-05-10 2010-12-22 株式会社カネカ Hair scalp composition
DE10123771B4 (en) 2001-05-16 2019-01-10 Beiersdorf Ag Use of electrolytes to strengthen the barrier function of the skin
EP1260212A1 (en) 2001-05-21 2002-11-27 Cognis France S.A. Cosmetic composition
EP1262167A1 (en) 2001-06-01 2002-12-04 Cognis France S.A. Cosmetic preparations containing an extract from germinating plants
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
US6506915B1 (en) 2001-06-14 2003-01-14 Daniel David West Synthesis of coenzyme Q10 ubiquinone
FR2826017B1 (en) 2001-06-15 2004-06-11 Cognis France Sa SURFACTANT MIXTURES
SE0102380D0 (en) 2001-07-02 2001-07-02 Macronova Ab Cream for the treatment of age changes in the skin of man
DE10133198A1 (en) 2001-07-07 2003-01-23 Beiersdorf Ag Use of topical compositions containing creatine and its precursors and derivatives e.g. to improve skin condition and to treat or prevent skin disorders
JP2003020495A (en) 2001-07-10 2003-01-24 Cognis Japan Ltd Oil and fat composition
CH695085A5 (en) 2001-07-13 2005-12-15 Mibelle Ag Cosmetics Formulations for care of the skin after laser treatment and / or chemical peels, and use of formulations.
TWI235146B (en) 2001-07-16 2005-07-01 Kaneka Corp Method of stabilizing reduced coenzyme q10 and method of acidic crystallization
PL213982B1 (en) 2001-07-27 2013-05-31 Nutricia Nv Enteral compositions for the prevention and/or treatment of sepsis
EP1281392A1 (en) 2001-08-02 2003-02-05 Cognis France S.A. Cosmetic or/and pharmaceutical compositions containing plant extracts
DE10139580A1 (en) 2001-08-10 2003-02-20 Beiersdorf Ag O/W emulsions useful e.g. cleansing, skin-care or anti-acne agents comprise a combination of steroids or fatty acids with optionally ethoxylated esters
DE10143962A1 (en) 2001-09-07 2003-03-27 Basf Ag Cosmetic and dermatological preparations in the form of O / W emulsions containing an amino-substituted hydroxybenzophenone
DE10143963A1 (en) 2001-09-07 2003-03-27 Basf Ag Cosmetic and dermatological preparations in the form of W / O emulsions containing an amino-substituted hydroxybenzophenone
DE10143964A1 (en) 2001-09-07 2003-03-27 Basf Ag Low-emulsifier or emulsifier-free systems of the oil-in-water type containing stabilizers and an amino-substituted hydroxybenzophenone
EP1432400A1 (en) 2001-09-18 2004-06-30 Ciba SC Holding AG Use of guaiol for treating the skin
DE10150725A1 (en) 2001-10-13 2003-04-17 Cognis Deutschland Gmbh Wax-based, anionic surfactant-free hazeing agent giving white non-lustrous haze in e.g. cosmetics contains an amphoteric surfactant, fatty acid partial glyceride, fatty acid polyglycol ester and optionally also a polyol
US7560123B2 (en) 2004-08-12 2009-07-14 Everett Laboratories, Inc. Compositions and methods for nutrition supplementation
US20060039956A1 (en) 2001-10-26 2006-02-23 Hermann Hensen Impregnating solution for cosmetic cloths
US6753325B2 (en) 2001-11-06 2004-06-22 The Quigley Corporation Composition and method for prevention, reduction and treatment of radiation dermatitis
US20030105031A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
DE10155769A1 (en) 2001-11-14 2003-05-22 Cognis Deutschland Gmbh Cosmetic and / or pharmaceutical emulsions
DE10160682A1 (en) 2001-12-11 2003-06-18 Cognis Deutschland Gmbh Cosmetic and/or pharmaceutical preparations, e.g. for skin or body care, comprise 2-methyl-1,3-propanediol diesters as emollients, having both lipophilic and hydrophilic properties
US6652891B2 (en) 2001-12-12 2003-11-25 Herbasway Laboratories, Llc Co-enzyme Q10 dietary supplement
DE10162026A1 (en) 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Highly concentrated flowable pearlescent concentrates
DE10162351A1 (en) 2001-12-18 2003-07-03 Cognis Deutschland Gmbh Cosmetic and / or pharmaceutical emulsions
ITRM20010755A1 (en) 2001-12-20 2003-06-20 Simonelli Giuseppe USE OF Q10 QUINONE FOR THE TREATMENT OF EYE DISEASES.
US20030129253A1 (en) 2002-01-03 2003-07-10 Milley Christopher J. Stable aqueous suspension
CN1617706A (en) 2002-01-18 2005-05-18 巴斯福股份公司 Cosmetic or dermatological preparations for preventing damages to skin caused by peroxides
TW200302056A (en) 2002-01-18 2003-08-01 Kaneka Corp Method for stabilizing reduced coenzyme Q10 and composition therefor
US7357918B2 (en) 2002-01-31 2008-04-15 Ciba Specialty Chemicals Corp. Micropigment mixtures
KR100969059B1 (en) 2002-02-12 2010-07-09 디에스엠 아이피 어셋츠 비.브이. Sunscreen compositions as well as dihydropyridines and dihydropyranes
DE60320380T2 (en) 2002-02-14 2009-05-20 Dsm Ip Assets B.V. COENZYM Q10 FORMULATIONS
EP1340486A1 (en) 2002-03-01 2003-09-03 Cognis France S.A. Use of sugar esters
US20030167556A1 (en) * 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
DE10254315A1 (en) 2002-03-15 2003-10-02 Cognis Deutschland Gmbh Cosmetic emulsion with aqueous phase(s) and water-insoluble oil phase, used for cosmetic and pharmaceutical purposes, preferably in body-care formulations, contains cyclohexylcyclohexane as oil body
DE10212528A1 (en) 2002-03-21 2003-10-02 Cognis Deutschland Gmbh Oil phases for cosmetic products
US7811594B2 (en) 2002-03-28 2010-10-12 Beiersdorf Ag Crosslinked oil droplet-based cosmetic or pharmaceutical emulsions
DE10213957A1 (en) 2002-03-28 2003-10-09 Beiersdorf Ag Crosslinked cosmetic or pharmaceutical phospholipid-containing gels and emulsions based on ethylene oxide-containing or propylene oxide-containing emulsifiers
DE10217474A1 (en) 2002-04-19 2003-11-06 Cognis Deutschland Gmbh Sun protection emulsion with foam dispenser
US20060193905A1 (en) 2002-05-14 2006-08-31 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
DE10223486A1 (en) 2002-05-27 2003-12-11 Beiersdorf Ag Cosmetic and / or dermatological preparation with 2,3-dibenzylbutyrolactones
ATE334654T1 (en) 2002-06-03 2006-08-15 Ciba Sc Holding Ag COMPOSITIONS PROTECTIVE FROM UV RAYS
DE10226018A1 (en) 2002-06-12 2003-12-24 Cognis Deutschland Gmbh Preparations with conjugated linoleic alcohol
US7147841B2 (en) 2002-06-17 2006-12-12 Ciba Specialty Chemicals Corporation Formulation of UV absorbers by incorporation in solid lipid nanoparticles
AU2003246592A1 (en) 2002-06-26 2004-01-19 Europroteome Ag Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases
US6953786B2 (en) 2002-10-01 2005-10-11 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
EP1421929A3 (en) 2002-11-21 2004-11-24 Cognis Deutschland GmbH & Co. KG Emollients and cosmetic preparations
DE10256881A1 (en) 2002-12-05 2004-06-24 Beiersdorf Ag New topical use of bis-arylimidazo [1,2-a] thiolane derivatives
US20040110848A1 (en) 2002-12-10 2004-06-10 Peffley Dennis M Method and kit for treating cancer
MXPA05007671A (en) 2003-01-20 2005-09-30 Ciba Sc Holding Ag Triazine derivatives as uv absorbers.
EP1589940A1 (en) 2003-02-03 2005-11-02 DSM IP Assets B.V. Novel stabilized cinnamic ester sunscreen compositions
US7258876B2 (en) 2003-02-05 2007-08-21 Craig Bozzacco Topical composition for treating infectious conditions of skin and mucosa
CN1208052C (en) * 2003-03-20 2005-06-29 上海家化联合股份有限公司 Coenzyme Q10 precursor liposome and preparation method
JP4764817B2 (en) 2003-03-24 2011-09-07 チバ ホールディング インコーポレーテッド Symmetric triazine derivatives
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20050000726A1 (en) 2003-06-06 2005-01-06 Honda Motor Co., Ltd. Resin encapsulated electronic component unit and method of manufacturing the same
US20060035981A1 (en) 2003-08-02 2006-02-16 Mazzio Elizabeth A Inhibition of anaerobic glucose metabolism and corresponding composition as a natural non-toxic approach to cancer treatment
US20080069779A1 (en) 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20050036976A1 (en) 2003-08-12 2005-02-17 Joel Rubin Topical skin care composition
EP1660023B1 (en) 2003-08-27 2009-01-07 Beiersdorf AG Capsule whose envelope is separately imperceptible during the topical use thereof
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
EP1670325A1 (en) 2003-09-29 2006-06-21 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
US7169385B2 (en) 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US20070196914A1 (en) 2003-10-02 2007-08-23 Sembiosys Genetics Inc. Methods for preparing oil bodies comprising active ingredients
DE10347218A1 (en) 2003-10-10 2005-05-12 Cognis Deutschland Gmbh Sunscreens
DE10347940A1 (en) 2003-10-15 2005-05-19 Cognis Deutschland Gmbh & Co. Kg Self-emulsifying preparations
US20070243180A1 (en) 2003-10-31 2007-10-18 Hozumi Tanaka Composition Containing Reduced Coenzyme Q
KR101008741B1 (en) 2003-11-05 2011-01-14 디에스엠 아이피 어셋츠 비.브이. Light protecting composition with reduced total amount of uv filter containing a polysiloxane-based uv filter
US20050100537A1 (en) 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
DE20320413U1 (en) 2003-11-17 2004-08-26 Beiersdorf Ag Cosmetic with sensitive ingredients
DK1718283T3 (en) * 2004-01-22 2013-04-22 Univ Miami Topical coenzyme Q10 formulations and methods of use.
US20050226947A1 (en) 2004-02-04 2005-10-13 Dale Kern Agents for sequestering serum aging factors and uses therefore
AU2005213895A1 (en) 2004-02-19 2005-09-01 Chemaphor Inc. Topical formulations for the treatment of skin conditions
US7780873B2 (en) 2004-02-23 2010-08-24 Texas A&M University System Bioactive complexes compositions and methods of use thereof
DE102004014615A1 (en) 2004-03-23 2005-10-13 Beiersdorf Ag Taurine-containing preparations for improving the skin barrier
KR20070001262A (en) 2004-04-06 2007-01-03 바스프 악티엔게젤샤프트 Cosmetic formulations comprising zno nanoparticles
US20050226858A1 (en) 2004-04-09 2005-10-13 Kaneka Corporation Compositions containing reduced coenzyme Q10 and carotenoid
US7723569B2 (en) 2004-04-30 2010-05-25 National Institute Of Agrobiological Sciences Method for producing ubiquinone-10 in plant
EP1755683A2 (en) 2004-05-18 2007-02-28 Kemijski Institut Water-soluble coenzyme q10 inclusion complex with beta-cyclodextrin, process of preparing, and use thereof
JP2008500301A (en) 2004-05-24 2008-01-10 ビーエーエスエフ　アクチェンゲゼルシャフト Keratin-binding polypeptide
WO2005123101A1 (en) 2004-06-18 2005-12-29 Symrise Gmbh & Co. Kg Blackberry extract
ES2380940T3 (en) 2004-06-28 2012-05-21 Dsm Ip Assets B.V. Cosmetic compositions containing protein hydrolysates
JP2006070016A (en) 2004-08-02 2006-03-16 Kaneka Corp Whitening composition containing reduced coenzyme q
US20060051462A1 (en) 2004-09-03 2006-03-09 Wang Jimmy X Self emulsifying compositions for delivering lipophilic coenzyme Q10 and other dietary ingredients
US7288263B2 (en) * 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
WO2006044738A2 (en) 2004-10-18 2006-04-27 Maroon Biotech Corporation Methods and compositions for treatment of free radical injury
AU2005300835B2 (en) 2004-11-02 2011-01-20 Dsm Ip Assets B.V. Additive for UV-sunscreen preparations
GB0424891D0 (en) 2004-11-11 2004-12-15 Boots Co Plc Topical compositions
US20060127384A1 (en) 2004-12-09 2006-06-15 Sergio Capaccioli Coenzyme Q10 as antiapoptotic agent
NO20045674D0 (en) 2004-12-28 2004-12-28 Uni I Oslo Thin films prepared with gas phase deposition technique
US20060286046A1 (en) 2005-01-05 2006-12-21 Haber C Andrew Skin care compositions
EP1849481A4 (en) * 2005-01-07 2012-11-28 Rohto Pharma Composition for external use
US20080207560A1 (en) * 2005-01-07 2008-08-28 Ayako Harada Composition For External Use
US20060188492A1 (en) 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
DE102005007980A1 (en) 2005-02-22 2006-02-23 Clariant Gmbh Cosmetic, pharmaceutical or dermatological preparation, useful as decorative agents e.g. mascara, eyelid shade and eyeliner, comprises copolymer wax comprising e.g. heterocyclic compounds and optionally aryl compounds
JP2008534619A (en) 2005-04-01 2008-08-28 ザイムス， エルエルシー Skin enhancement using CoQ10 as a delivery system
US20070053985A1 (en) 2005-08-24 2007-03-08 Kaneka Corporation Coenzyme Q10-containing fine particle with excellent dispersibility
US20070071779A1 (en) 2005-09-26 2007-03-29 Leggit Ingenuity, Llc Compositions for delivering lipophilic agents to the intestinal mucosa and method of making thereof
US20070092469A1 (en) 2005-10-26 2007-04-26 Eric Jacobs Topically applied Glucosamine Sulfate and all its related, precursor, and derivative compounds significantly increases the skin's natural produciton of hyaluronic acid for the rejuvenation of healthier younger-looking skin; while PhosphatidylCholine is required to replace its deficiency caused by topical Dimethylaminoethanol (DMAE)
US8506956B2 (en) 2005-10-31 2013-08-13 Kaneka Corporation Method for stabilizing reduced coenzyme Q10
US9265792B2 (en) 2005-11-16 2016-02-23 Patricia A. Riley Integument cell regeneration formulation
CA2631713A1 (en) 2005-12-02 2007-09-13 Sirtris Pharmaceuticals, Inc. Modulators of cdc2-like kinases (clks) and methods of use thereof
US20070172436A1 (en) 2006-01-23 2007-07-26 Jerry Zhang Nonaqueous ascorbic acid compositions and methods for preparing same
US20070184076A1 (en) 2006-02-07 2007-08-09 Unger Evan C Liquid-filled nanodroplets for anti-cancer therapy
US20070184041A1 (en) 2006-02-09 2007-08-09 Burja Adam M Methods and compositions related to production of coenzyme q10
US7335384B2 (en) 2006-03-17 2008-02-26 4K Nutripharma International Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
JP5286081B2 (en) 2006-04-28 2013-09-11 株式会社カネカ Method for stabilizing reduced coenzyme Q10
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
WO2007126086A1 (en) 2006-04-28 2007-11-08 Kaneka Corporation Method for purification of reduced coenzyme q10
US20080020022A1 (en) 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
US8894993B2 (en) 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
JP2012526828A (en) * 2009-05-11 2012-11-01 バーグ バイオシステムズ，エルエルシー Methods for treating metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmentally affecting factors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219472A1 (en) * 2002-05-23 2003-11-27 Pauletti Giovanni M. Compositions and method for transmucosal drug delivery and cryoprotection
US20050281772A1 (en) * 2004-06-17 2005-12-22 Bromley Philip J Compositions for mucosal delivery of agents

Also Published As

Publication number Publication date
ES2755840T3 (en) 2020-04-23
US20080233183A1 (en) 2008-09-25
AU2014202278C1 (en) 2017-04-13
NO20093032L (en) 2009-10-22
EP2136787A4 (en) 2013-07-31
AU2008228764A1 (en) 2008-09-25
AU2014202278A1 (en) 2014-05-22
US8454945B2 (en) 2013-06-04
CA2823407C (en) 2016-10-18
CA2823407A1 (en) 2008-09-25
EP3607937A1 (en) 2020-02-12
MX337408B (en) 2016-03-03
MX2009010170A (en) 2009-11-26
WO2008116135A2 (en) 2008-09-25
ZA201400071B (en) 2014-12-23
US20210015748A1 (en) 2021-01-21
AU2014202278B2 (en) 2016-06-02
US20130202683A1 (en) 2013-08-08
EP2136787B1 (en) 2019-08-21
BRPI0809164B1 (en) 2020-08-04
BRPI0809164B8 (en) 2023-02-28
AU2008228764B2 (en) 2014-05-08
CA2680825C (en) 2013-10-29
BRPI0809164A2 (en) 2014-09-16
US20230147697A1 (en) 2023-05-11
MX363435B (en) 2019-03-22
EP2136787A2 (en) 2009-12-30
US10588859B2 (en) 2020-03-17
CA2680825A1 (en) 2008-09-25
MX352434B (en) 2017-11-24

Similar Documents

Publication Publication Date Title
WO2008116135A3 (en) Topical formulations having enhanced bioavailability
WO2010127099A3 (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2008066899A3 (en) Nanoparticulate formulations and methods for the making and use thereof
WO2009100441A3 (en) Depot formulations
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2011051354A3 (en) Transdermal pharmaceutical compositions comprising active agents
EP2093237A4 (en) Cancer therapeutic agent comprising anti-hb-egf antibody as active ingredient
SG178948A1 (en) Fatty acid niacin conjugates and their uses
PL2081547T3 (en) Galenic form for the trans-mucosal delivery of active ingredients
HK1131154A1 (en) Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient
WO2008070670A3 (en) Enhanced immediate release formulations of topiramate
WO2013090278A3 (en) Intranasal dexmedetomidine compositions and methods of use thereof
EP2078731A4 (en) Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
WO2012075081A3 (en) High-strength testosterone undecanoate compositions
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
UA103930C2 (en) Normal;heading 1;heading 2;heading 3;COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF PARASITIC DISEASES
WO2005077122A3 (en) Compounds and compositions as lxr modulators
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2010092088A3 (en) Use of hydrophobin as a spreading agent
IL196606A (en) Use of escin for the manufacture of pharmaceutical preparations and pharmaceutical compositions comprising escin for treating diseases
WO2005077124A3 (en) Compounds and compositions as lxr modulators
EP2321265A4 (en) Inositol and trehalose derivatives and pharmaceutical compositions for treating neurodegenerative diseases comprising the same
WO2011093831A3 (en) Effervescent formulations comprising cefprozil as active agent
WO2009092892A3 (en) Novel composition for treating the side effects of anticancer treatments
WO2008053356A3 (en) Immediate release oxymorphone compositions and methods of using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08732635

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008228764

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2680825

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008732635

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/010170

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008228764

Country of ref document: AU

Date of ref document: 20080321

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0809164

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090921